• 187
  • 39
  • 收藏

Pfizer, BioNTech say third dose neutralizes Omicron variant

Tiger Newspress2021-12-08

Pfizer and biontech stocks narrowed their losses in premarket trading after they provided update on Omicron variant.

  • Preliminary laboratory studies demonstrate that three doses of the Pfizer-BioNTech COVID-19 Vaccine neutralize the Omicron variant (B.1.1.529 lineage) while two doses show significantly reduced neutralization titers
  • Data indicate that a third dose of BNT162b2 increases the neutralizing antibody titers by 25-fold compared to two doses against the Omicron variant; titers after the booster dose are comparable to titers observed after two doses against the wild-type virus which are associated with high levels of protection
  • As 80% of epitopes in the spike protein recognized by CD8+ T cells are not affected by the mutations in the Omicron variant, two doses may still induce protection against severe disease
  • The companies continue to advance the development of a variant-specific vaccine for Omicron and expect to have it available by March in the event that an adaption is needed to further increase the level and duration of protection – with no change expected to the companies’ four billion dose capacity for 2022

Pfizer Inc. and BioNTech SE today announced results from an initial laboratory study demonstrating that serum antibodies induced by the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) neutralize the SARS-CoV-2 Omicron variant after three doses. Sera obtained from vaccinees one month after receiving the booster vaccination (third dose of BNT162b2 vaccine) neutralized the Omicron variant to levels that are comparable to thoseobserved for the wild-type SARS-CoV-2 spike protein after two doses.

Sera from individuals who received two doses of the current COVID-19 vaccine did exhibit, on average, more than a 25-fold reduction in neutralization titers against the Omicron variant compared to wild-type, indicating that two doses of BNT162b2 may not be sufficient to protect against infection with the Omicron variant. However, as the vast majority of epitopes targeted by vaccine-induced T cells are not affected by the mutations in Omicron, the companies believe that vaccinated individuals may still be protected against severe forms of the disease and are closely monitoring real world effectiveness against Omicron, globally.

A more robust protection may be achieved by a third dose as data from additional studies of the companies indicate that a booster with the current COVID-19 vaccine from Pfizer and BioNTech increases the antibody titers by 25-fold. According to the companies’ preliminary data, a third dose provides a similar level of neutralizing antibodies to Omicron as is observed after two doses against wild-type and other variants that emerged before Omicron. These antibody levels are associated with high efficacy against both the wild-type virus and these variants. A third dose also strongly increases CD8+T cell levels against multiple spike protein epitopes which are considered to correlate with the protection against severe disease. Compared to the wild-type virus, the vast majority of these epitopes remain unchanged in the Omicron spike variant.

“Although two doses of the vaccine may still offer protection against severe disease caused by the Omicron strain, it’s clear from these preliminary data that protection is improved with a third dose of our vaccine,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. “Ensuring as many people as possible are fully vaccinated with the first two dose series and a booster remains the best course of action to prevent the spread of COVID-19.”

“Our preliminary, first dataset indicate that a third dose could still offer a sufficient level of protection from disease of any severity caused by the Omicron variant,” said Ugur Sahin, M.D., CEO and Co-Founder of BioNTech. “Broad vaccination and booster campaigns around the world could help us to better protect people everywhere and to get through the winter season. We continue to work on an adapted vaccine which, we believe, will help to induce a high level of protection against Omicron-induced COVID-19 disease as well as a prolonged protection compared to the current vaccine.”

While these results are preliminary, the companies will continue to collect more laboratory data and evaluate real-world effectiveness to assess and confirm protection against Omicron and inform the most effective path forward. On November 25, the companies started to develop an Omicron-specific COVID-19 vaccine. The development will continue as planned in the event that a vaccine adaption is needed to increase the level and duration of protection against Omicron. First batches of the Omicron-based vaccine can be produced and are planned to be ready for deliveries within 100 days, pending regulatory approval. Pfizer and BioNTech have tested other variant-specific vaccines as well, which have produced very strong neutralization titers and a tolerable safety profile. Based on this experience the companies have high confidence that if needed they can deliver an Omicron-based vaccine in March 2022. The companies have also previously initiated clinical trials with variant-specific vaccines (Alpha, Beta, Delta & Alpha/Delta Mix) and data from these studies will be submitted to regulatory agencies around the world to help accelerate the process of adapting the vaccine and gaining regulatory authorization or approval of an Omicron-specific vaccine, if needed. The companies have previously announced that they expect to produce four billion doses of BNT162b2 in 2022, and this capacity is not expected to change if an adapted vaccine is required.

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

举报

评论39

  • PearlynCSY
    ·2021-12-24
    Covid-19: Israel plans to give fourth dose of vaccine to over-60s and healthcare workers
    回复
    举报
  • Mabelicious
    ·2021-12-09
    Anyone can enlighten why their shares fell on Wed despite the news?
    回复
    举报
    收起
    • ladyman
      Stock trading is risky, and retail investors must be cautious in trading.
      2021-12-10
      回复
      举报
    • cutieee
      Retail investors always lag behind in news.
      2021-12-10
      回复
      举报
    • dimsum
      If I knew, I would be as famous as Buffett.
      2021-12-09
      回复
      举报
    查看更多 1 条评论
  • TK360
    ·2021-12-09
    Nice 
    回复
    举报
  • Cvt
    ·2021-12-09
    Good to know
    回复
    举报
    收起
    • SeC
      2021-12-10
      回复
      举报
  • JT1806
    ·2021-12-09
    Hopefully it works
    回复
    举报
  • robot1234
    ·2021-12-09
    Will earn many more billions
    回复
    举报
  • andrew123
    ·2021-12-09
    Like
    回复
    举报
  • evey77
    ·2021-12-09
    Gd news. Key here is to save lives, less about thestock performance. 
    回复
    举报
    收起
    • ET77
      All about their bottomline…
      2021-12-09
      回复
      举报
  • burstthepulp
    ·2021-12-09
    Great ariticle, would you like to share it?
    回复
    举报
  • DZL
    ·2021-12-08
    Booster shot for robust protection against Omicron
    回复
    举报
    收起
    • iHuat
      Yalor
      2021-12-08
      回复
      举报
    • DZL
      revenue boost for Pfizer and BioNTech
      2021-12-08
      回复
      举报
  • Evie85
    ·2021-12-08
    Like
    回复
    举报
  • Gene7
    ·2021-12-08
    Thanks for the insight. Plz like 
    回复
    举报
    收起
    • JeremyKok
      hi. please like and comment back. thank you.
      2021-12-09
      回复
      举报
    • PS153
      ok
      2021-12-08
      回复
      举报
  • Tiramisu2020
    ·2021-12-08
    Like 
    回复
    举报
  • HHTan
    ·2021-12-08
    Please like 
    回复
    举报
    收起
    • JeremyKok
      hi. please like and comment back. thank you.
      2021-12-09
      回复
      举报
    • Tiramisu2020
      Like
      2021-12-08
      回复
      举报
  • Liuliusg
    ·2021-12-08
    Ok
    回复
    举报
  • madnugget
    ·2021-12-08
    Pfe to 60!
    回复
    举报
  • Yonakazuk
    ·2021-12-08
    Sure Bo?
    回复
    举报
  • peanutnotes
    ·2021-12-08
    Wow, that's amazing
    回复
    举报
  • HermioneG
    ·2021-12-08
    Ok
    回复
    举报
  • kenjoe
    ·2021-12-08
    Positive development. 
    回复
    举报
 
 
 
 

热议股票

 
 
 
 
 

7x24